Novo Nordisk stock is trying to stabilize near $44 after one of the sharpest drawdowns seen among large pharmaceutical companies in recent years. The latest catalyst is the UK approval of an oral Wegovy pill priced at $149 per month, a move designed to expand access but one that also underscores how aggressively the company is resetting price expectations.
The shares traded around $44.48 on June 16, up from $43.88 at the prior close, leaving the stock far below its June 2024 all-time closing high of $137.40. That decline of more than 67% has turned Novo Nordisk into a high-stakes turnaround story rather than a growth favorite.
The central question for investors is whether lower pricing, broader distribution and new coverage channels can offset lost momentum in the obesity drug race, where Eli Lilly has been steadily gaining ground.
Key Facts
- Novo Nordisk traded near $44.48 on June 16 after closing at $43.88 in the prior session, with an intraday range of $44.19 to $44.79.
- The stock is down more than 67% from its all-time closing high of $137.40 reached in June 2024.
- The oral Wegovy pill was approved in the UK on June 11 at a 25 mg dose and launched at $149 per month.
- Novo Nordisk said roughly 80% of Wegovy pill users were new to GLP-1 therapy.
- The company authorized a DKK 15 billion share buyback while Medicare GLP-1 coverage expansion is set to begin on July 1.
Novo Nordisk stock
Novo Nordisk stock sits at the intersection of falling prices and expanding access. The company is betting that a lower-cost oral obesity treatment can reach patients who were previously priced out of the market, especially as healthcare systems and insurers look for cheaper ways to provide GLP-1 therapies. The UK approval of oral Wegovy gives Novo Nordisk another regulatory win and strengthens its position in a market still dominated by injectable drugs.
That matters because the company is no longer being judged simply on growth. Investors are now focused on whether Novo Nordisk can protect its obesity franchise while pricing pressure intensifies across the US market. Political scrutiny, compounded copies of semaglutide and direct competition from Eli Lilly have all chipped away at the premium pricing that once supported the stock’s higher valuation.
The company still has scale, brand recognition and major exposure to a weight-loss market that could approach $100 billion by the end of the decade. But the market is demanding proof that the volume-over-price strategy can translate into durable revenue and earnings growth before assigning a richer multiple again.
Novo Nordisk is no longer priced as a market leader with uncontested momentum; it is priced as a company that must prove lower prices can still produce higher long-term value.
Why the $149 oral Wegovy launch matters
The oral Wegovy launch is strategically important because it broadens the company’s addressable market. Pills are easier to distribute, easier for some patients to start, and potentially easier for payers to support than injectable therapies. If the company can convert large numbers of first-time users, it may be able to rebuild growth through patient volume rather than premium pricing.
That strategy comes with near-term tradeoffs. Lower realized prices can pressure margins well before scale benefits appear in financial results. This is one reason the stock remains near its lows even after a quarterly earnings beat and new approvals: the market wants confirmation, not just a credible plan.
Implications for Investors
For investors, Novo Nordisk presents a classic recovery setup with unusually wide valuation disagreement. Some analysts see a deeply discounted global obesity franchise with meaningful upside if execution improves. Others see a structural reset in drug pricing that could limit returns for years. The stock’s current level suggests the market is still leaning toward caution.
Several factors could influence the next move. Medicare coverage expansion beginning July 1 could open a large new patient base, particularly among older adults who were previously excluded from broad access. Continued uptake of oral Wegovy, especially among patients new to GLP-1s, would support the thesis that the company is expanding the market rather than merely cannibalizing its injectable products.
At the same time, risks remain significant. Eli Lilly continues to win share and maintain stronger narrative momentum with investors. Novo Nordisk also faces pipeline questions after weaker-than-expected enthusiasm around CagriSema, concentration risk from its GLP-1 franchise, and uncertainty around future employer coverage for weight-loss medicines. The disclosed IT security incident adds another layer of operational sensitivity, even if it was described as limited.
The first-quarter figures offered some support for the bull case. Obesity-care revenue grew 22% on an adjusted constant-currency basis, while the company delivered an earnings-per-share beat and raised 2026 guidance for adjusted sales and operating profit. Yet the broader picture remains complicated by foreign exchange effects and lower pricing, as shown by 2025 full-year results that included sales of DKK 309.1 billion and operating profit of DKK 127.7 billion.
Capital returns also matter here. A DKK 15 billion buyback at depressed levels signals management sees value in the current stock price. That does not guarantee a bottom, but it can provide support if operating performance stabilizes and investors begin to believe the worst of the repricing cycle has passed.
Technically, the stock appears to be building a base above its 52-week low of $35.12. A sustained move through the high-$40s would likely be viewed as an early sign that sentiment is improving. A break back toward the low-$30s would revive fears that pricing damage is more permanent than temporary.
Over the next several quarters, the key data points will be pill adoption, reimbursement trends, competitive share shifts and whether lower pricing can still drive enough demand to restore earnings momentum. If those pieces fall into place, Novo Nordisk could shift from a value trap narrative to a credible turnaround. If not, the stock may remain under pressure despite its lower valuation.
VIP Algorithmic Setups
